A REVIEW: ON THE STATUS AND TREATMENT OF DEPRESSION IN PRESENT TIME AMONG ADOLESCENT AND YOUNGER ADULTS IN INDIA.

AAYUSH THAKUR¹, MANEESH BANYAL², JYOTI GUPTA³, SWATI JOSHI⁴

Student, Department of pharmacy, IEC University, Baddi, Himachal Pradesh
Assistant professor, Department of pharmacy, IEC University, Baddi, Himachal Pradesh
HEAD OF DEPARTMENT, Department of pharmacy, IEC University, Baddi, Himachal Pradesh
Assistant professor, Department of pharmacy, IEC University, Baddi, Himachal Pradesh

Abstract

All age groups, including children and adolescents, are susceptible to depression, a common mental illness. Depression is commonly connected with substantial impairment in children and adolescents. The leading global contributor to disease and incapacity is depression. Research documenting the incidence of depression among children and adolescents indicate large percentages of youngsters in both groups with depressed symptoms. This review aims to analyze Indian research on depression is among adolescent and younger adults. This article also have major goal is to examine the scientific data on adolescent depression screening, diagnosis, and treatment, with a focus on primary care settings, history of depression, pathology and treatment of depression. The risk factors for moderate to severe depressive disorders in adolescents and young adults were discovered in the current investigation. At the end in this review we will offer some recommendations for treating depression and enhancing general mental health.

Key words: Depression, adolescents, pathology, treatment

INTRODUCTION

Depression is a widespread mental health condition that affects millions of people globally. It will also characterized by persistent feelings of sadness, hopelessness, and a lack of interest or pleasure in activities that were once enjoyable. Depression can significantly impact an individual's daily life, causing physical symptoms such as fatigue and changes in appetite, as well as causing difficulties with work, relationships, And self-esteem. Despite its prevalence, depression is often misunderstood and stigmatized, leading many people to struggle in silence. However, it is treatable through a combination of therapy, medication, and with depression can successfully manage their symptoms and improve their quality of life. [1] [6]

History of Depression

Depression has been recognized as a mental health disorder for thousands of years, with descriptions of symptoms dating back to ancient civilizations such as Greece and Egypt. The ancient Greeks recognized depression as a medical condition, with the physician Hippocrates describing it as a form of "melancholia." During the medieval period, depression was often seen as a spiritual affliction, with sufferers being treated by priests or exorcists.[2]

In the 19^{th} century, depression became more widely recognized as a medical condition, and advances in understanding the brain led to new theories about the causes and treatments for depression. By the mid- 20^{th} century, the first modern antidepressants were developed, which revolutionized the treatment of depression.

Despite these advancements, depression remained stigmatized and misunderstood for many years, with sufferers often being blamed for their condition or told to "snap out of it." In the 1980_s and 1990_s , however,

There was growing recognition of depression as a real and treatable illness, and the development of new, effective antidepressants further improved treatment options.[23]

Today, depression is widely recognized as a serious and common mental health disorder, and these is a growing body of research into its causes and treatments. While there is still much that is unknown about depression, advances in understanding the brain and new treatments continue to offer hope to those who struggle with this condition. [1]

In conclusion, depression has a long and complex history, with recognition and understanding of the condition evolving over time. Today, depression is widely recognized as a serious and treatable mental health disorder, and advances in treatment options continue to offer hope to those who struggle with it. [2][7]

Symptoms of Depression

Studies have reported that depression is characterized by a wide range of symptoms, including somatic symptoms, guilt, suicidal behavior, delusions, and sleep disturbances.[37,39] Somatic symptoms are common in depression, with some studies indicating that they are the most common manifestation of depression in India. Indian subjects with depression have also been found to have hypochondriacal ideas regarding their bodies and bodily functions. Pain has also been identified as a common symptom of depression.[11,26,12]

Other symptoms that are frequently reported in depressed individuals include depressed mood, difficulties with work, late insomnia, somatic anxiety, initial insomnia, psychic anxiety, suicidal ideation, retardation, loss of insight, middle insomnia, genital symptoms, hypochondriasis, gastrointestinal symptoms, agitation, and diurnal variation.[36,25,39] Depersonalization, paranoid, and obsessional symptoms are reported less frequently. Guilt is present in about half of the cases, although studies have shown that guilt is less commonly seen in eastern populations compared to the West.[39,44]

Studies comparing symptomatology across regions within India have found some differences. For example, significantly more subjects from north India report joylessness, disruption in social functioning, lack of self-confidence, early morning awakening, lack of appetite, feeling of pressure, other psychological symptoms, psychomotor restlessness, mood worsening in the morning, subjective experience of memory loss, retardation, and guilt feeling; while subjects from south India more frequently report hypochondriasis.[36] Lack of interest is reported more commonly in subjects from north India, while reduced self-confidence, delusions, and suicidal thoughts are seen more often in the south Indian sample.

Furthermore, some studies have attempted to distinguish the phenomenology in depression from negative symptoms of schizophrenia and the phenomenology in dysthymia.[39,45,38] It has been hypothesized that guilt may not be an integral part of depression in Indian subjects and is actually a consequence of depression, according to the karma theory. However, guilt is still present in a significant percentage of Indian subjects with depression.

In terms of suicidal thinking, about two-thirds of depressed subjects have been reported to exhibit suicidal behavior. Suicidal ideation has been classified into four broad categories: ideas to kill oneself, a mere wish to die, a wish to be killed, and an unclassifiable category. Those who attempt suicide are at a higher risk of indulging in further suicidal behavior, compared to those who do not attempt. However, presence of suicidal behavior does not necessarily predict overall poor clinical outcome.[34,27]

In terms of sleep architecture, depressed individuals generally have lesser total sleep time, longer sleep latency, frequent awakenings, greater wake-after-sleep onset and offset times, lesser sleep efficiency, and a tendency to wake up earlier than controls.[21,23,45] Severity of depression has also been found to be associated with differences in sleep architecture.

Type of Depression

There are several type of depression, including:

- 1. Major Depression Disorder (MDD) Characterized by persistent feelings of sadness, loss of interest, and decreased activity levels.
- 2. Persistent Depressive Disorder (PDD) Also known as Dysthymia, a type of chronic depression lasting for at least two years.
- 3. Bipolar Disorder- Characterized by alternating episodes of depression and mania.
- 4. Seasonal Affective Disorder (SAD) A type of depression that occurs during specific seasons, usually winter.
- 5. Postpartum Depression A type of depression experienced by some women after giving birth.
- 6. **Psychotic Depression** A type of depression with symptoms of both depression and psychosis, such as delusions or hallucinations.

It's important to note that depression is a complex condition and some individuals may experience symptoms that do not fit neatly into one of these categories. A mental health professional can diagnose and provide the appropriate treatment for an individual's specific type of depression.

PATHOPHYSIOLOGY OF DEPRESSION

The exact Pathophysiology of depression is not yet fully understood, but it is thought to involve a combination of biological, genetic, environmental, and psychological factors.

- 1. Neurotransmitter imbalances: Depression is thought to be associated with imbalances in neurotransmitters, such as serotonin, nor-epinephrine, and dopamine, which regulate mood, sleep, appetite, and energy.
- 2. Hormonal changes: Depression can also be associated with hormonal changes, such as those that occur during menopause or thyroid dysfunction.
- 3. Inflammation: Chronic inflammation has been linked to the development of depression, and the activation of immune cell and release of cytokines have been shown to have a negative impact on mood and behavior.
- 4. Genetics: Depression can run in families, and genetic factors may contribute to an individual's susceptibility to the condition.
- 5. Stressful life events: Traumatic or stressful life events, such as the loss of a loved one, a divorce, or financial problems, can trigger or worsen depression.
- 6. Brain structure and function: Research has shown that certain brain regions, such as the amygdale and the hippocampus, are involved in depression, and that alterations in their structure and function may condition.

Overall, depression is a complex condition that likely results from the interaction of multiple factors, and the Pathophysiology of depression may differ from person to person.[1] [3]

CAUSES OF DEPRESSION

Depression is a mood disorder that affects millions of people worldwide, and it can have a significant impact on a person's daily life. While there is no one-size-fits-all cause for depression, there are several known risk factors that can contribute to the development of the disorder. In this response, we will explore the causes of depression, including genetic, environmental, and psychological factors.[24][9][3]

Genetic Factors

There is evidence to suggest that depression may have a genetic component, meaning that certain genes may predispose individuals to the disorder. Studies have shown that depression tends to run in families, and people with a first-degree relative (such as a parent or sibling) who has depression are more likely to develop the disorder themselves. Additionally, research has identified specific genes that are associated with depression, although the exact role that these genes play in the development of the disorder is still not fully understood.

Environmental Factors

Several environmental factors can contribute to the development of depression, including:

Stress: High levels of stress can trigger depression, particularly in people who are already vulnerable to the disorder. Stressful life events, such as the death of a loved one, a divorce, or job loss, can all increase the risk of depression.

Trauma: Traumatic experiences, such as physical or sexual abuse, can increase the risk of depression. Post-traumatic stress disorder (PTSD) is a related condition that can also lead to depression.

Chronic Illness: Chronic illnesses, such as cancer, heart disease, or diabetes, can increase the risk of depression. This may be due to the stress of dealing with the illness, as well as the physical changes that come with chronic conditions.

Substance Abuse: Substance abuse, particularly of drugs and alcohol, can increase the risk of depression. This is because these substances can alter brain chemistry, making it more difficult to regulate mood.

Psychological Factors

Several psychological factors can contribute to the development of depression, including:

Personality: Certain personality traits, such as low self-esteem, pessimism, and a tendency to worry, can increase the risk of depression.

Negative Thinking: Negative thinking patterns, such as excessive self-criticism, overgeneralization, and all-ornothing thinking, can contribute to the development of depression.

Childhood Experiences: Childhood experiences, such as abuse, neglect, or a dysfunctional family environment, can increase the risk of depression. These experiences can lead to negative thinking patterns and a reduced ability to cope with stress.

In summary, depression is a complex disorder with multiple causes. While there is no single cause of depression, research has identified several risk factors that can increase the likelihood of developing the disorder. These include genetic factors, environmental factors such as stress and trauma, and psychological factors such as negative thinking patterns and childhood experiences. It is important to note that each person's experience with depression is unique, and treatment plans should be tailored to each individual's specific needs. If you or someone you know is struggling with depression, seeking professional help is an important step towards recovery. [5] [3]

Disorder	Share of global population with disorder (2017) [difference across countries]	Number of people with the disorder (2017)	Share of males:females with disorder (2017)
Any mental health disorder	10.7%	792 million	9.3% males 11.9% females
Depression	3.4% [2-6%]	264 million	2.7% males4.1% females
Anxiety disorders	3.8% [2.5-7%]	284 million	2.8% males4.7% females
<u>Bipolar disorder</u>	0.6%	46 million	0.55% males 0.65% females
Eating disorders (clinical anorexia & bulimia)	0.2%	16 million	0.13% males 0.29% females
<u>Schizophrenia</u>	0.3%	20 million	0.26% males 0.25% females
Any mental or substance use disorder	13% [11-18%]	970 million	12.6% males 13.3% females
Alcohol use disorder	1.4%	107 million	2% males 0.8% females
Drug use disorder (excluding alcohol)	0.9%	71 million	1.3% males 0.6% females

Fig.1: Number of people with the disorder

TREATMENT OF DEPRESSION

Depression is a common mental health condition characterized by feelings of sadness, hopelessness, and loss of interest in activities that were once enjoyed. It can be a debilitating condition that affects many aspects of a person's life, including their work, relationships, and overall well-being.

Fortunately, depression is treatable, and there are a range of options available for those who are struggling with this condition. The most effective treatment for depression is often a combination of medication, psychotherapy, and lifestyle changes.

Medication: Antidepressant medications can be effective in alleviating symptoms of depression by regulating the balance of chemicals in the brain. The most commonly prescribed medications for depression are selective serotonin reuptake inhibitors (SSRIs), which help increase the levels of serotonin, a neurotransmitter that affects mood and emotions. Other classes of antidepressant medications include Tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIS), and atypical antidepressants. Antidepressant medications can take several weeks to start working, and it is important to work with a healthcare professional to find the right medication and dosage that works best for you.

Psychotherapy: Psychotherapy is also known as talk therapy, can also be an effective treatment for depression. One of the most common forms of psychotherapy for depression is cognitive behavioral therapy (CBT), which helps individuals identify and change negative thought patterns. This therapy can help individuals learn coping strategies, improve communication and relationship skills, and gain a more positive outlook on life. Other forms of psychotherapy that can be effective for depression include interpersonal therapy, behavioral activation therapy, and psycho-dynamic therapy.

Lifestyle Changes: Making positive changes to one's lifestyle can also play an important role in the treatment of depression. Regular exercise, a balanced diet, and sufficient sleep can help alleviate symptoms of depression and promote overall well-being. Engaging in activities that bring joy and fulfillment, such as hobbies or volunteering, can also help improve mood and self-esteem. Additionally, limiting or avoiding alcohol and drugs can help minimize symptoms of depression.

Alternative Therapies: For some individuals, alternative therapies such as mindfulness, meditation, and yoga may be helpful in treating depression. These therapies can help individuals manage stress, improve mood, and increase self-awareness. Some people may also find relief from depression through complementary therapies such as acupuncture, massage, or herbal remedies. It's important to consult with a healthcare professional before starting any alternative therapies.

Electroconvulsive Therapy (**ECT**): ECT is a medical procedure that is sometimes used to treat severe depression when other treatments have not been effective. It involves the use of electrical stimulation to the brain to produce a seizure. ECT has been shown to be effective in alleviating symptoms of depression, but it is usually a last resort due to its potential side effects.

Treatment for depression can be challenging, and it is important to be patient and persistent in seeking help. A combination of medication, psychotherapy, and lifestyle changes can be effective for most individuals, but it may take time to find the right combination of treatments that work best for you. It is also important to have support from loved ones, a healthcare professional, or a support group to help you through the process.

In conclusion, depression is a treatable condition, and there are a range of options available for those who are struggling with this condition. It is important to work with a healthcare professional to determine the best course of treatment for your individual needs and to have patience and persistence in seeking help. Remember, recovery from depression is possible, and there is hope for a brighter future. [5] [9]

MEDICATION OF DEPRESSION

Diagnosis of depression typically involves a thorough evaluation by a mental health professional, including a medical and psychiatric history and a psychological assessment. Antidepressant medications are some of the most common medications for depression.

Antidepressant: Antidepressants are a type of medication used to treat depression and other mood disorders. They work by adjusting the levels of certain chemicals in the brain, such as serotonin, nor epinephrine, and dopamine that regulate mood and emotions.



Antidepressant

Antidepressants are a class of medications used to treat depression and other mental health conditions. They work by changing the balance of chemicals in the brain, including serotonin, norepinephrine, and dopamine.

There are several types of antidepressants, including selective serotonin reuptake inhibitors (SSRIs), serotoninnorepinephrine reuptake inhibitors (SNRIs), Tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (maois). Each type works in slightly different ways, but all aim to alleviate the symptoms of depression by increasing the availability of certain neurotransmitters in the brain.

Antidepressants are usually prescribed by a psychiatrist or other mental health professional. It's important to take them exactly as directed, and to continue taking them for the full length of time prescribed, even if symptoms improve. It may take several weeks for the full effects of the medication to be felt.

Like all medications, antidepressants can have side effects, and it's important to discuss these with your healthcare provider. Some common side effects of antidepressants include nausea, dizziness, dry mouth, and insomnia. In rare cases, antidepressants can also increase the risk of suicidal thoughts or behaviors, especially in children, teenagers, and young adults.

If you're struggling with depression or another mental health condition, antidepressants may be a helpful part of your treatment plan. However, they are just one tool among many, and it's important to also seek therapy, engage in self-care practices, and make lifestyle changes that support mental health.[6] [4]

Reversible inhibitors of MAO-A (RIMAs)

Reversible inhibitors of monoamine oxidase A (MAO-A), commonly known as RIMAs, are a class of drugs used primarily as antidepressants. These drugs work by blocking the action of MAO-A, an enzyme that breaks down neurotransmitters such as serotonin, norepinephrine, and dopamine.

Unlike traditional MAO inhibitors, which irreversibly bind to the MAO enzyme and can cause dangerous interactions with certain foods and medications, RIMAs bind to the enzyme reversibly. This means that their effects are more easily controlled, and there is less risk of dangerous interactions.

Rimas were developed as an alternative to traditional MAO inhibitors, which were known to cause a number of adverse effects and potentially serious drug interactions. RIMAs were designed to provide the benefits of MAO inhibition without the risks associated with traditional MAO inhibitors.

Examples of RIMAs include moclobemide and befloxatone. These drugs have been shown to be effective in treating depression and anxiety, and they have a relatively low incidence of side effects. However, as with all medications, RIMAs can cause adverse effects in some individuals, including nausea, dizziness, and insomnia.

Overall, RIMAs represent an important development in the treatment of depression and other mood disorders, offering a safer and more effective alternative to traditional MAO inhibitors. [7][8]

Here are some of the pharmacological actions of (RIMAs):

- 1. Antidepressant effects: RIMAs are primarily used for the treatment of depression. They are believed to work by increasing the levels of serotonin, norepinephrine, and dopamine in the brain, which are important neurotransmitters involved in the regulation of mood and emotions.
- 2. Anxiolytic effects: RIMAs have also been shown to have Anxiolytic (anti-anxiety) effects. By increasing the levels of serotonin and other neurotransmitters, they can help reduce symptoms of anxiety and improve overall mood.
- 3. Improved cognition: RIMAs have been shown to improve cognitive function in patients with depression. They can enhance memory, attention, and executive function, which are often impaired in individuals with depression.
- 4. Fewer side effects: RIMAs are considered to have fewer side effects compared to other antidepressants. They do not cause the same level of sedation, weight gain, or sexual dysfunction as other antidepressants, which can be a major advantage for some patients.
- 5. Reduced risk of drug interactions: RIMAs have a lower risk of drug interactions compared to other antidepressants, which can be especially important for patients who are taking multiple medications.

Tricyclic antidepressant (TCAs)

Tricyclic antidepressants (TCAs) are a class of medications used primarily to treat major depression. They were first introduced in the 1950s and were one of the first types of antidepressants to be developed. TCAs work by blocking the reuptake of neurotransmitters such as serotonin and norepinephrine, which can help regulate mood and relieve symptoms of depression.

In addition to depression, TCAs are also used to treat other conditions such as anxiety disorders, obsessivecompulsive disorder, and chronic pain. However, they are generally not considered first-line treatments for these conditions due to their potential for side effects and the availability of newer medications with fewer risks.

TCAs are called "Tricyclic" because of their three-ring chemical structure. Some commonly prescribed tcas include amitriptyline, imipramine, nortriptyline, and desipramine. These medications are typically taken orally, either once or multiple times per day, and can take several weeks to start working.

Like all medications, TCAs can have side effects, which can include dry mouth, constipation, blurred vision, dizziness, weight gain, and sexual dysfunction. They can also be dangerous in overdose, which is why they are often prescribed in lower doses and monitored closely by healthcare professionals. [7] [8]

Here are some of the pharmacological actions of (TCAs):

- **1.** Inhibition of reuptake of norepinephrine and serotonin: TCAs block the reuptake of norepinephrine and serotonin by the presynaptic neuron, which increases the concentration of these neurotransmitters in the synaptic cleft.
- 2. Blockade of histamine receptors: TCAs can block histamine receptors in the brain, which can cause sedation and weight gain.
- **3.** Blockade of muscarinic acetylcholine receptors: TCAs can also block muscarinic acetylcholine receptors, which can lead to dry mouth, constipation, and urinary retention.
- **4.** Blockade of alpha-adrenergic receptors: TCAs can block alpha-adrenergic receptors, which can cause orthostatic hypotension (a drop in blood pressure upon standing up) and dizziness.
- **5.** Blockade of sodium channels: TCAs can also block sodium channels, which can lead to cardiac toxicity, especially in overdose.

Selective serotonin reuptake inhibitors (SSRIs)

Selective serotonin reuptake inhibitors (SSRIs) are a class of antidepressant drugs that work by increasing the levels of the neurotransmitter serotonin in the brain. SSRIs are the most commonly prescribed antidepressants and are used to treat a wide range of mental health conditions, including depression, anxiety disorders, obsessive-compulsive disorder (OCD), and post-traumatic stress disorder (PTSD).

SSRIs work by blocking the reuptake of serotonin, which is a chemical messenger that regulates mood, appetite, and sleep. By preventing the reuptake of serotonin, SSRIs increase the availability of the neurotransmitter in the brain, which can lead to an improvement in mood and a reduction in anxiety.

Some commonly prescribed SSRIs include fluoxetine (Prozac), sertraline (Zoloft), escitalopram (Lexapro), and paroxetine (Paxil). These medications are generally well-tolerated and have fewer side effects than older antidepressants, such as Tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (maois).

However, like all medications, SSRIs can have side effects, such as nausea, insomnia, and sexual dysfunction. It is important to work closely with a healthcare provider to determine the most appropriate medication and dosage for an individual's specific needs. Additionally, SSRIs can interact with other medications, so it is important to inform healthcare providers of all medications, supplements, and herbs being taken.[7][8]

The pharmacological actions of SSRIs include:

- 1. Inhibition of serotonin reuptake: SSRIs work by blocking the reuptake of serotonin into the presynaptic neuron, thereby increasing the concentration of serotonin in the synaptic cleft. This leads to increased activation of serotonin receptors and enhanced serotonin neurotransmission.
- 2. Desensitization of serotonin receptors: Prolonged activation of serotonin receptors can lead to desensitization, which reduces the effectiveness of serotonin signaling. SSRIs can reduce this effect by reducing the amount of serotonin released from the presynaptic neuron.
- 3. Increased neuroplasticity: SSRIs can increase the growth and branching of neurons in certain regions of the brain, leading to improved neural plasticity and adaptability.
- 4. Modulation of the hypothalamic-pituitary-adrenal (HPA) axis: SSRIs can affect the HPA axis, which is involved in the stress response. This can lead to decreased cortisol levels and improved stress management.
- 5. Anti-inflammatory effects: SSRIs can reduce inflammation in the brain by inhibiting the production of pro-inflammatory cytokines.

Serotonin and noradrenaline reuptake inhibitors (SNIRIs)

Serotonin and noradrenaline reuptake inhibitors (SNIRIs) are a class of drugs commonly used to treat depression and anxiety disorders. They work by increasing the levels of two important neurotransmitters, serotonin and norepinephrine, in the brain.

SNRIs work by blocking the reuptake of both serotonin and norepinephrine into the neurons that released them, thereby increasing the amount of these neurotransmitters available in the synapse to bind with their receptors. This results in increased neurotransmission, which is thought to be responsible for the therapeutic effects of SNRIs.

SNRIs are similar in mechanism of action to selective serotonin reuptake inhibitors (SSRIs), which are also used to treat depression and anxiety disorders. However, SNRIs additionally affect norepinephrine reuptake, whereas SSRIs primarily target serotonin.

Some commonly prescribed SNRIs include venlafaxine, duloxetine, and desvenlafaxine. These drugs have been shown to be effective in treating depression, anxiety, and chronic pain conditions.

As with all medications, there may be potential side effects associated with SNRIs. Some common side effects include nausea, dizziness, headache, and insomnia. SNRIs may also increase blood pressure and heart rate, so they should be used with caution in individuals with cardiovascular conditions. It is important to discuss potential side effects with a healthcare provider before starting any medication.[7][8]

Here are some of the pharmacological actions of SNRIs:

- 1. Increased levels of serotonin and norepinephrine: SNRIs prevent the reuptake of serotonin and norepinephrine in the brain, leading to increased levels of these neurotransmitters. This can help improve mood, reduce anxiety, and relieve pain.
- 2. Antidepressant effects: SNRIs are commonly used as antidepressants because they can help alleviate symptoms of depression, such as sadness, hopelessness, and fatigue.
- 3. Anxiolytic effects: SNRIs can also help reduce symptoms of anxiety, such as nervousness, tension, and worry.
- 4. Analgesic effects: SNRIs can be effective in treating chronic pain conditions such as fibromyalgia and neuropathic pain.
- 5. Cardiovascular effects: SNRIs can increase heart rate and blood pressure due to the effects of norepinephrine on the cardiovascular system.
- 6. Gastrointestinal effects: SNRIs can cause nausea, vomiting, and diarrhea, which are thought to be related to their effects on serotonin receptors in the gut.
- 7. Sexual side effects: SNRIs can cause sexual dysfunction, such as decreased libido, difficulty achieving or maintaining an erection, and delayed ejaculation, due to their effects on serotonin and norepinephrine levels in the brain.

Atypical antidepressant

Atypical antidepressants are a class of medications used to treat depression and other mental health disorders. Unlike traditional antidepressants, which primarily target the neurotransmitters serotonin and norepinephrine, atypical antidepressants work through a variety of mechanisms, such as increasing dopamine or norepinephrine levels, or modulating glutamate or GABA receptors.

Some examples of atypical antidepressants include bupropion (Wellbutrin), trazodone (Desyrel), mirtazapine (Remeron), and vilazodone (Viibryd). These medications may be used alone or in combination with other antidepressants or mood stabilizers, depending on the individual's specific symptoms and needs.

Atypical antidepressants are generally well-tolerated and have fewer side effects compared to traditional antidepressants, but they may still cause side effects such as dry mouth, constipation, dizziness, and nausea. It is important to work closely with a healthcare provider to find the right medication and dosage for an individual's specific needs.[7][8]

Here are some of the pharmacological actions of atypical antidepressants:

- 1. Norepinephrine and dopamine reuptake inhibition: Bupropion is a medication that inhibits the reuptake of both norepinephrine and dopamine, leading to an increase in their levels in the brain. This mechanism of action is different from that of SSRIs, which primarily affect serotonin levels.
- 2. Serotonin receptor modulation: Mirtazapine acts as an antagonist at certain serotonin receptors, which leads to an increase in serotonin and norepinephrine levels in the brain.
- 3. Serotonin partial agonism: Vilazodone is a medication that acts as a partial agonist at serotonin receptors, leading to an increase in serotonin levels. It also inhibits the reuptake of serotonin, similar to SSRIs.
- 4. Serotonin and norepinephrine reuptake inhibition: Trazodone is a medication that inhibits the reuptake of both serotonin and norepinephrine, leading to an increase in their levels in the brain.
- 5. Serotonin receptor agonism and reuptake inhibition: Vortioxetine is a medication that acts as a serotonin receptor agonist and inhibits serotonin reuptake, leading to an increase in serotonin levels in the brain.

Drug Treatment

It explains that around 50-65% of patients respond positively to the first antidepressant prescribed, but there is no one superior antidepressant. Choosing the right antidepressant is guided by a variety of factors, including the patient's symptoms, side effect profile, medical and psychiatric co-morbidities, prior response, and cost.

The article also discusses the monoamine hypothesis, a biological theory that posits depression is caused by under activity in the brain of monoamines such as dopamine, serotonin, and norepinephrine. This hypothesis has been a major focus of research in the field of Pathophysiology and pharmacotherapy for over 25 years.

Monoamine oxidase inhibitors (maois) and Tricyclic antidepressants (TCAs) were discovered in the 1950s to be effective in treating depression. Maois block the degradation of monoamine neurotransmitters, leading to increased concentrations in the brain, while TCAs prevent the reuptake of various neurotransmitters.

Nowadays, the most commonly prescribed antidepressants are selective serotonin reuptake inhibitors (SSRIs), which prevent the reuptake of serotonin, thereby increasing the level of active serotonin in the brain. Other novel antidepressants affect norepinephrine reuptake or different receptors on nerve cells.

The article also explains that while antidepressants increase serotonin levels, they can initially make patients feel worse for the first few weeks of treatment. One explanation for this is that 5-ht2a receptors evolved as a saturation signal, telling animals to stop searching for food, mates, etc., and to start looking for predators. Stimulation of 5-ht2a receptors achieves this, but if the threat is long-lasting, the animal needs to start eating and mating again. The fact that it survived shows that the threat was not as dangerous as it felt. Therefore, the number of 5-ht2a receptors decreases through a process known as down regulation, and the animal goes back to its normal behavior.

The article also mentions that stimulation or blocking of different receptors on a cell affects its genetic expression. A recent finding had shown that neurogenesis, and thus changes in brain morphogenesis, mediate the effects of antidepressant drugs. Additionally, antidepressants may have some longer-term effects due to the promotion of neurogenesis in the hippocampus, an effect found in mice. Other animal research suggested that antidepressants can affect the expression of genes in brain cells by influencing "clock genes."

The article concludes by noting that while antidepressant medication is an effective treatment for depression, it should be closely monitored for possible worsening of depression or suicidality, especially at the beginning of therapy or when the dose changes. Overall, the choice of antidepressant should be based on individual patient needs and preferences, with careful consideration of potential side effects, co-morbidities, and cost. [3][5][9]

Frequent Initial Visits: patients will require frequent visits early in Treatment to assess response to intervention, suicidal ideation, Side effects, and psychosocial support systems.

Continuation Therapy: continuation therapy (9-12 months after acute symptoms resolve) will decrease the incidence of relapse of major depression. Long term maintenance or life-time drug Therapy should be considered for selected patients based on their History of relapse and other clinical features.

Education/Support: patient education and support are Essential. Social stigma and patient resistance to the diagnosis of Depression will continue to be a problem.

CONCLUSION

Depression is a common and serious mental health disorder that can have a significant impact on a person's quality of life. It can be affect anyone, regardless of age, gender, race, or Social class. If you or someone you know is grapple with depression, it's important to seek help as soon as possible. In this response, we will provide some suggestions for managing depression and improving overall mental health.

1. Seek Professional Help

The first step in managing depression is to seek professional help. A mental health professional can provide a proper diagnosis, recommend appropriate treatment options, and provide ongoing support. Treatment for depression may include therapy, medication, or a combination of both. It's important to work with a mental health professional to find the right treatment plan for your specific needs.

2. Practice Self-Care

Self-care is an essential component of managing depression. This means taking care of yourself both physically and mentally. Some self-care strategies that may be helpful include getting enough sleep, exercising regularly, eating a healthy diet, and engaging in activities that bring you joy. It's also important to take time for yourself, whether that means practicing meditation, taking a relaxing bath, or reading a book.

3. Connect with Supportive People

Social support is crucial in managing depression. This may include connecting with friends, family members, or a support group. It can be helpful to talk to people who understand what you're going through and can offer support and encouragement. If you don't have a support system in place, consider reaching out to a mental health professional for guidance on how to build one.

4. Challenge Negative Thoughts

Depression can lead to negative thinking patterns, such as self-blame, self-doubt, and hopelessness. Challenging these negative thoughts can help to break the cycle of depression. It may be helpful to keep a journal to track your thoughts and identify negative patterns. Once you've identified these patterns, you can work on replacing negative thoughts with more positive ones.

5. Practice Mindfulness

Awareness is the practice of being present in the moment and fully engaged in what you're doing. It can help to decrease stress, anxiety, and depression. Mindfulness practices may include meditation, deep breathing exercises, or simply focusing on the present moment. Incorporating mindfulness into your daily routine can help to improve your overall mental health.

6. Set Realistic Goals

Depression can make it difficult to feel motivated and accomplish tasks. Setting realistic goals can help to provide a sense of purpose and accomplishment. It's important to start small and work your way up to larger goals. Celebrating small accomplishments along the way can also help to boost self-esteem and motivation.

7. Manage Stress

Stress can exacerbate depression symptoms. Finding healthy ways to manage stress can help to reduce symptoms and improve overall mental health. This may include practicing relaxation techniques, such as deep breathing or meditation, or engaging in stress-reducing activities, such as exercise or spending time in nature.

In conclusion, depression is a complex and serious mental health disorder that can have a significant impact on a person's quality of life. While there is no one-size-fits-all approach to managing depression, there are several strategies that can be helpful, including seeking professional help, practicing self-care, connecting with supportive people, challenging negative thoughts, practicing mindfulness, setting realistic goals, and managing stress. It's important to remember that recovery from depression is a journey and may take time, but with the right support and strategies in place, it is possible to manage symptoms and improve overall mental health.

References

- 1. Kessler R.C., McGonagale K.A., Zhao S., et al., Lifetime And 12-month prevalence of DSM-IIIR psychiatric Disorders in the United States, Results from the National Comorbidity Survey Arch Gen Psychiatry, 51, 8-19, (2003)
- 2. Robins L., Regier D., Psychiatric Disorders in America, New York: Free Press (2004)
- 3. Judd L.L., The clinical course of unipolar major depressiveDisorders Arch Gen Psychiatry, 54, 989-991 (2008)
- 4. Greenberg P.E., Stiglin L.E., Finkelstein S.N. and Berndt E.R., The economic burden of depression in 1990, J Clan Psychiatry, 54, 405-418 (2009)
- 5. Blair-West G.W., Mellsop G.W. and Eyeson-Annan M.L., Down-rating lifetime suicide risk in major depression, Acta Psychiatr Scand, 95, 259-263 (2010)
- 6. Harris E.C., Barraclough B., Suicide as an outcome for Mental disorders, A meta-analysis Br J Psychiatry, 170, 205-228. (2001)
- 7. Neal R.M. and Baldwin R.C., Screening for anxiety and Depression in elderly medical outpatients, Age Aging, 23, 461-464 (2004)
- 8. Okimoto J.T., BarnesR.F., veith R.C., raskind M.A., inui T.S. And carter W.B., screening for depression in geriatric Medical patients, am j psychiatry, 139, 799-802 (2002)
- 9. ParkersonG.R. Jr. And Broadhead W.E., Screening for Anxiety and depression in primary care with the Duke Anxiety-Depression Scale, Fem. Med., 29, 177-181 (2007)

- Salokangas R.K., Poutanen O. And Stengard E., Screening for depressioninprimarycare, Developmentand Validation of the Depression Scale, a screening instrument for depression, Acta Psychiatr Scand., 92, 10-16 (2005)
- 11. Khan Z.A. and Ghosh A.R., Involvement of nnos in the Antidepressant-like effect of Withaferin-A in rats, Journal Of Pharmaceutical and Biomedical Sciences (JPBMS),7, 1-2 (2010)
- 12. Murray L., Stanley C., Hooper R., king F., fiori-cowley A, the role of infant factors in postnatal depression and Mother-infant interactions, dev med child neurol, 38, 109 119 (2000)
- 13. Musselman D., Evans d. And Nemeroff C., the Relationship of depression to cardiovascular disease, arch Gen psychiatry, 55, 580-592 (2002)
- 14. Consensus development panel, nimh/nih consensus Development conference statement mood disorders: Pharmacologic prevention of recurrences, am j psychiatry, 142, 469-476 (2003)
- 15. Pennix B.W., Guralnik J.M., Ferrucci L., simonsick E.M., DeegD.J., WallaceR.B., depressive symptoms and Physical decline in community-dwelling older persons Jama, 276, 1720-1726 (2007)
- 16. American psychiatric association, diagnostic and Statistical manual of mental disorders, fourth edition Washington, dc: American psychiatric association (2000)
- 17. Wells K.B., StewartA., hays R.D.Et al., the functioning And well-being of depressed patients results from the Medical outcomes study, jama, 262, 914-919 (2002)
- 18. Howland R., general health, health care utilization, and Medical comorbidity inDysthymia, Int j psychiatry med 23, 211-238 (2005)
- 19. Wells K.B., burnam M.A., RogersW., hays R., camp P., The course of depression in adult outpatients results from The medical outcomes study, arch gen psychiatry, 49, 788-794 (2002)
- 20. Williams J.W.JR, kerberC.A., mulrowC.D., medina a.And aguilar C., depressive disorders in primary care: Prevalence, functional disability and identification, j gen Intern med., 10, 7-12 (2008)
- Wagner r., burns B.J., Yarnall K., Sigmon a., walker r. And gaynessB.N., minor depression in family practice: Functional morbidity, comorbidity, service utilization and Outcomes, psycho med., 30(6), 1377-1390 (2000)
- 22. Cooper-PatrickL., CrumR.M., ford D.E., characteristics of patients with majordepression who received care in General medical and specialty mental health settings, med Care, 32, 15-24 (2009)
- 23. Paykel E. And priest R., recognition and management of Depression in general practice, consensus statement, bmj 305, 1198-1202 (2002)
- 24. Simon G.E., von korff M. And durham M.L., predictors of outpatient mental health utilization byprimary care Patients in a health maintenance organization, am j Psychiatry, 151, 908-913 (2004)
- 25. Song F., Freemantle n. And sheldon T.A., et al., selective Serotonin reuptake inhibitors: metaanalysis of efficacy and acceptability, bmj,306, 683-687 (2006)
- KesslerR.C., NelsonC.B., Mcgongale K.A., liuJ., Swartz m. And blazer dg., comorbidity of dsmiiir Major depressive disorder in the general population, Results from the us national comorbidity survey, br J Psychiatry, 168, 17-30 (2006)
- 27. PincusH.A., Tanielian T.L.And marcusS.C., et al., Prescribing trends in psychotropic medications, primary Care, psychiatry and other medical specialities, jama, 279, 526-531 (2007)
- 28. SimonG.E.And von korffm., recognition, Management, and outcomes of depression in primary care, Arch fam med., 4, 99-105 (2007)

- 29. Gerber P.D., Barrett J., BarrettJ., Manheimer E., Whiting R. And Smith R., recognition of depression by internists in Primary care, a comparison of internist and gold standard Psychiatric assessments, J gen intern med,4,7-13 (2003)
- 30. Klinkman M.S., competing demands in psychosocial Care, a model for the identification and treatment of Depressive disorders in primary care, gen hosp psychiatry, 19, 98-111 (2001)
- 31. Borowsky S.J., RubensteinL.V., MeredithL.S., camp P., Jackson-TricheM. And wells K.B., who is at risk of Nondetection of mental health problems in primary care, JGen intern med, 15, 381-388 (2000)
- 32. Linde K., Mulrow C.D.And ST. John's wort for depression, Cochrane review, the Cochrane library, (2008)
- 33. Us preventive services task force. Guide to clinical Preventive services, 2nd ED, Alexandria, Va., international Medical publishing, (2009)
- 34. American college of physicians, ACP-ASIM clinical Practice guidelines: current and future projects, Available at: http://www.acponline.org/sci-Policy/guidelines/projects.htm. (2009)
- 35. Feightner J.W., early detection of depression. In, Canadian Task force on the periodic health examination, Canadian Guide to clinical preventive health care, Ottawa, health Canada, 450-454 (2004)
- Arthur A., Jagger C., Lindesay J., Graham C. and Clarke M., Using an annual over-75 health check to screen for Depression, validation of the short geriatric depression Scale (GDS15) within General Practice, Int J Geriatr Psychiatry, 14, 431-439 (2008)
- 37. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. *Global Burden of Disease and Risk Factors*. Washington: The World Bank; 2006.
- Poongothai S, Pradeepa R, Ganesan A, Mohan V. Prevalence of depression in a large urban South Indian population - The Chennai Urban Rural Epidemiology Study (CURES-70) *PloS One.* 2009;4:E7185.
- 39. Ponnudurai R, Somasundaram O, Balakrishnan S, Srinivasan N. Depression-a study of 80 cases. *Indian J Psychiatry*. 1981;23:256–8.
- 40. Jain RK, Aras RY. Depression in geriatric population in urban slums of Mumbai. *Indian J Pub Health.* 2007;51:112–3.
- 41. Chandran M, Tharyan P, Muliyil J, Abraham S. Post-partum depression in a cohort of women from a rural area of Tamil Nadu, India Incidence and risk factors. *British J Psychiatry*. 2002;181:499–504.
- 42. Bagadia VN, Jeste DV, Doshi SU, Shah LP. Depression: A clinical study of 233 cases. *Indian J Psychiatry*. 1973;15:224–30.
- 43. Sethi BB, Sharma M. Depressive disorders and family constellation. *Indian J Psychiatry*. 1980;22:69–73.
- 44. Venkoba Rao A, Madhavan T. Depression and suicide behaviour in the aged. *Indian J Psychiatry*. 1983;25:251–9.
- 45. Chatterjee RN, Mukherjee SP, Nandi DN. Life events and depression. *Indian J Psychiatry*. 1981;23:333–7.